Can I join a CJC-1295 (no DAC) clinical trial?

No CJC-1295 (no DAC) trial is recruiting right now. New trials appear on ClinicalTrials.gov.

CJC-1295 (no DAC) clinical trials

ClinicalTrials.gov lists 1 registered trial of CJC-1295 (no DAC): 0 recruiting or about to, 0 running, 0 completed. The largest is A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (120 people).

1registered trials

0recruiting now

0running

0completed

0in phase 3

0with results posted

Stopped or withdrawn 1

CJC-1295 (no DAC) research (grade D)CJC-1295 (no DAC) prices Search ClinicalTrials.gov

Where CJC-1295 (no DAC) is in testing

Registered trials by phase. Phase 3 trials are the large ones that decide approval.

0Early phase 1First doses in people

0Phase 1Safety and dosing

1Phase 2Does it work?

0Phase 3Large confirmatory trials

0Phase 4After approval

0Not phasedObservational and other

Timeline

Each bar runs from a trial's start to its planned end; faded bars have no end date. Click a bar to open the trial.

RecruitingRunningCompletedStopped or withdrawnStatus unknownToday

Stopped early or withdrawn 1

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

TerminatedPhase 2120 peopleRandomizedConjuChem2005-12 → 2006-09

Studying: Obesity, HIV Infections · NCT00267527

About this trial

This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC 1295 or placebo. The objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity.

Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (CJC-1295) in the listed interventions.